Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Taking The Long View With Its Therapeutic Franchises

This article was originally published in The Pink Sheet Daily

Executive Summary

The Big Pharma has only recently entered the diabetes drug market, but has plans to make a significant impact on how the disease is treated. During a meeting with analysts, J&J highlighted the deals it’s made and the multiple indications it will pursue within the metabolic space.

Advertisement

Related Content

Biosimilars Battle: Celltrion’s Remsima Takes On J&J’s Remicade In Korea
FDA Approves Simponi For Ulcerative Colitis
Biosimilar Remicade Will Pit Rising Cost Pressures Against Prescriber Caution
J&J Gains FDA OK For First-In-Class Type 2 Diabetes Drug Invokana

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS075735

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel